GlyTherix Ltd

GlyTherix Ltd, is a targeted radiotherapy company with a clinical stage antibody product, Miltuximab®, showing an excellent safety profile in high unmet need cancers. Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue. There is a large addressable market in the USA and Europe of US$21.7 billion per annum. The company has a strong proprietary and intellectual property position covering the Miltuximab® antibody, epitope and the antigen. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. Miltuximab® precisely delivers targeted radiation to cancer cells. The company chelates a low energy 89Zirconium isotope to the antibody for diagnostic imaging. Image positive patients can then receive a dose of Miltuximab® that is chelated to the high energy isotope 177Lutetium resulting in a cell destroying dose directly at the site of the cancer. GlyTherix also has a pre-clinical program underway investigating the use of alpha particles, ie 225Actinium and 212Lead. GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse. events. Miltuximab® will be used in both the Phase Ib and US Phase 2 trials as an antibody theranostic. The company has entered an exclusive manufacturing, supply & distribution agreements with reliable isotope suppliers ANSTO and Cyclowest Holdings, both highly regarded nuclear medicine companies in Australia. Agreements with US based CDMOs and isotope suppliers for our planned US trials are also in place. GlyTherix has a strong management and research team and a highly experienced clinical advisory panel who have been intimately involved in commercialisation of targeted radiotherapies that are marketed in the US and elsewhere.